Last reviewed · How we verify
Reversal of superficial neuromuscular blockade
Reversal of superficial neuromuscular blockade is a Neuromuscular blockade reversal agent Small molecule drug developed by Pontificia Universidade Catolica de Sao Paulo. It is currently FDA-approved for Reversal of superficial neuromuscular blockade induced by neuromuscular blocking agents during general anesthesia.
This drug reverses neuromuscular blockade by antagonizing the effects of neuromuscular blocking agents at the neuromuscular junction.
This drug reverses neuromuscular blockade by antagonizing the effects of neuromuscular blocking agents at the neuromuscular junction. Used for Reversal of superficial neuromuscular blockade induced by neuromuscular blocking agents during general anesthesia.
At a glance
| Generic name | Reversal of superficial neuromuscular blockade |
|---|---|
| Sponsor | Pontificia Universidade Catolica de Sao Paulo |
| Drug class | Neuromuscular blockade reversal agent |
| Target | Acetylcholinesterase or neuromuscular blocking agents (depending on specific agent) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Neuromuscular blocking agents are used during anesthesia to paralyze muscles; reversal agents work by either inhibiting acetylcholinesterase (allowing acetylcholine to accumulate and compete with the blocking agent) or by acting as selective relaxant binding agents that encapsulate and inactivate the blocking drug. This restores neuromuscular transmission and allows spontaneous breathing and muscle function to return.
Approved indications
- Reversal of superficial neuromuscular blockade induced by neuromuscular blocking agents during general anesthesia
Common side effects
- Bradycardia
- Increased salivation
- Muscle fasciculations
- Nausea
Key clinical trials
- The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block
- Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium (PHASE4)
- Efficacy of Sugammadex in Magnesium Pretreated Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reversal of superficial neuromuscular blockade CI brief — competitive landscape report
- Reversal of superficial neuromuscular blockade updates RSS · CI watch RSS
- Pontificia Universidade Catolica de Sao Paulo portfolio CI
Frequently asked questions about Reversal of superficial neuromuscular blockade
What is Reversal of superficial neuromuscular blockade?
How does Reversal of superficial neuromuscular blockade work?
What is Reversal of superficial neuromuscular blockade used for?
Who makes Reversal of superficial neuromuscular blockade?
What drug class is Reversal of superficial neuromuscular blockade in?
What development phase is Reversal of superficial neuromuscular blockade in?
What are the side effects of Reversal of superficial neuromuscular blockade?
What does Reversal of superficial neuromuscular blockade target?
Related
- Drug class: All Neuromuscular blockade reversal agent drugs
- Target: All drugs targeting Acetylcholinesterase or neuromuscular blocking agents (depending on specific agent)
- Manufacturer: Pontificia Universidade Catolica de Sao Paulo — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for Reversal of superficial neuromuscular blockade induced by neuromuscular blocking agents during general anesthesia
- Compare: Reversal of superficial neuromuscular blockade vs similar drugs
- Pricing: Reversal of superficial neuromuscular blockade cost, discount & access